Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor α agonist

Metabolism: Clinical and Experimental

Volumn 57, Issue 11, 2008, Pages 1516-1525

  Chen, Xiaoli ^a   Matthews, Jay ^a   Zhou, Lubing ^a   Pelton, Patricia ^a   Liang, Yin ^a   Xu, Jun ^a   Yang, Maria ^a   Cryan, Ellen ^a   Rybczynski, Philip ^a   Demarest, Keith ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CIPROFIBRATE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; BODY WEIGHT; CONTROLLED STUDY; DIET; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY EXPENDITURE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GLUCOSE TOLERANCE; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIVER CELL; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RODENT; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN A-I; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; ENERGY METABOLISM; FATTY ACIDS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERINSULINISM; INDANS; INSULIN RESISTANCE; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OXIDATION-REDUCTION; PHENYLUREA COMPOUNDS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 53649097298     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.06.005     Document Type: Article

References (40)

1. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
2. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
3. Stolar M.W., and Chilton R.J. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 25 (2003) B4-B31
4. Linsel-Nitschke P., and Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev 4 (2005) 193-205
5. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
6. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
7. Fonseca V.A. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 92 (2003) 50J-60J
8. Brown P.J., Winegar D.A., Plunket K.D., et al. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARa agonist with potent lipid-lowering activity. J Med Chem 42 (1999) 3785-3788
9. Willson T.M., and Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1 (1997) 235-241
10. Duez H., Chao Y., Hernandez M., et al. Reduction of atherosclerosis by the peroxisome proliferators-activated receptor a agonist fenofibrate in mice. J Biol Chem 277 (2002) 48051-48057
11. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 92 (2003) 34J-41J
12. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
13. Kobayashi M., Shigeta Y., Hirata Y., et al. Improvement of glucose tolerance in NIDDM by clofibrate: randomized double-blind study. Diabetes Care 11 (1988) 495-499
14. Mikhailidis D.P., Mathur S., Barradas M.A., et al. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis. J Cardiovasc Pharmacol 16 (1990) S26-S29
15. Guerre-Millo M., Gervois P., Raspe E., et al. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275 (2000) 16638-16642
16. Kim H., Haluzik M., Asghar Z., et al. Peroxisome proliferator-activated receptor-a agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52 (2003) 1770-1778
17. Bergeron R., Yao J., Woods J.W., et al. Peroxisome proliferators-activated receptor (PPAR)-a agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: a comparison with PPARg agonism. Endocrinol 147 (2006) 4252-4262
18. Matthews J.M., Chen X., Zhou L., et al. Design and synthesis of indane-ureido-thioisobutyric acids: a novel class of PPARa agonists. Bioorg Med Chem Lett 17 (2007) 6773-6778
19. Chen X., Osborne M.C., Rybczynski P.J., et al. Pharmacological profile of a novel, non-TZD PPARg agonist. Diabetes Obes Metab 7 (2005) 536-546
20. Burris T.P., Pelton P.D., Zhou L., et al. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Mol Endocrinol 13 (1999) 410-417
21. Moon A., and Rhead W.J. Complementation analysis of fatty acid oxidation disorders. J Clin Invest 79 (1987) 59-64
22. Minnich A., Tian N., Byan L., et al. A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280 (2001) E270-E279
23. Staels B., and Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharm Des 3 (1997) 1-14
24. Staels B., and Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis 137 Suppl (1998) S19-S23
25. Lawrence J.W., Li Y., Chen S., et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferators-activated receptor (PPAR) a. J Biol Chem 276 (2001) 31521-37527
26. Eriksson M., Carlson L.A., Miettinen T.A., et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 101 (1999) 594-598
27. Bone A.J., and Gwilliam D.J. Animal syndromes of non-insulin-dependent diabetes mellitus. In: Pickup J.C., and Williams G. (Eds). Textbook of diabetes. 2nd ed (1997), Blackwell Science, London 4-10
28. Buse J.B., Tan M.H., Prince M.J., et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6 (2004) 133-156
29. Füllert S., Schneider F., Haak E., et al. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 87 (2002) 5503-5506
30. Rubin E.M., Krauss R.M., Spangler E.A., et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991) 265-267
31. Liu A.C., Lawn R.M., Verstuyft J.G., et al. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein{a} in transgenic mice. J Lipid Res 35 (1994) 2263-2267
32. Paszty C., Maeda N., Verstuyft J., et al. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 94 (1994) 899-903
33. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 (1997) 3-10
34. Boden G., Lebed B., Schatz M., et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50 (2001) 1612-1617
35. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 (2000) 171-176
36. Auwerx J. Improving metabolism by increasing energy expenditure. Nat Med 12 (2006) 44-45
37. Schmitz-Peiffer C. Signaling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cell Signal 12 (2000) 583-594
38. Khan B.B., and Flier J. Obesity and insulin resistance. J Clin Invest 106 (2000) 473-481
39. Lazar M.A. The humoral side of insulin resistance. Nat Med 12 (2006) 43-44
40. Lee S.S., Pineau T., Drago J., et al. Targeted disruption of the isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022